XML 13 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Income Statement [Abstract]        
Net sales $ 1,384,429 $ 279,883 $ 4,252,704 $ 845,513
Cost of sales 942,738 73,988 2,981,657 237,707
Gross Profit 441,691 205,895 1,271,047 607,806
Operating expenses        
Compensation and related expenses 361,829 101,137 1,077,340 301,301
Professional fees 82,608 29,237 277,282 91,059
General and administrative expenses 204,958 57,580 382,857 206,841
Total operating expenses 649,395 187,954 1,737,479 599,201
Operating Income (Loss) (207,704) 17,941 (466,432) 8,605
Interest (expense) (9,992) (14,422) (15,805) (33,048)
Net Income (Loss) Before Taxes (217,696) 3,519 (482,237) (24,443)
Deferred income tax benefit 4,600 13,200
Net Income (Loss) (217,696) 8,119 (482,237) (11,243)
Net income (loss) attributable to noncontrolling interests 8,955 6,439
Net income (loss) attributable to Immudyne, Inc. $ (226,651) $ 8,119 $ (488,676) $ (11,243)
Basic and diluted (loss) per share attributable to Immudyne, Inc. $ (0.01) $ 0.00 $ (0.02) $ (0.00)
Average number of common shares outstanding        
Basic 34,427,087 30,650,000 31,917,873 30,663,306
Diluted $ 34,427,087 $ 30,650,000 $ 31,917,873 $ 30,663,306